7,583.50

+9.00

+0.12%

51,958.00

-175.00

-0.34%

28,310.50

+183.00

+0.65%

Russell 2000 Futures

2,831.70

+13.90

+0.49%

4.9060

+0.0120

+0.25%

20.86

-0.29

-1.38%

3,975.00

+5.40

+0.14%

77,278.57

-514.91

-0.66%

Crude Oil Dec 26

94.04

-2.42

-2.51%

US Private Equity

10,836.30

-14.33

-0.13%

Paris - Delayed Quote EUR

AB Science S.A. (AB.PA)

0.5310 -0.0080 (-1.48%)

As of 11:37:46 AM GMT+1. Market Open.

Loading Chart for AB.PA

Chart Range Bar

Interval:

In partnership with ChartIQ

AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.

AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.

AB Science today reports its revenues for the first half of 2026 and provides an update on its activities

AB Science today reports its revenues for the first half of 2026 and provides an update on its activities

AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection

AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection

AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026

AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026

AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

AB Science announces the successful completion of a EUR 2.3 million private placement

AB Science announces the successful completion of a EUR 2.3 million private placement

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

AB Science reports its revenues for the year 2025 and provides an update on its activities

AB Science reports its revenues for the year 2025 and provides an update on its activities

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

AB Science provides an update on its clinical development program.

AB Science provides an update on its clinical development program.

Mobilize your Website

View Site in Mobile | Classic

Share by: